申请人:Aventis Pharma S.A.
公开号:US20030060609A1
公开(公告)日:2003-03-27
The invention concerns compounds of formula (I), in which Y is oxygen, N-Nalc 1 or NOalc 2: X represents hydrogen, hydroxyl, alkyl, alkenyl, alkynyl, alkoxy, CONOR or NRcRd, Rc and Rd being hydrogen or alkyl; Z represents hydrogen, halogen or free, etherified or esterified OH; R 2 hydrogen or halogen; R 3 hydrogen, alkyl or halogen; R hydrogen or alkyl; R 1 hydrogen, alkyl, alkenyl or alkynyl; R 5 hydrogen or O-alkyl; R 6 alkyl or CH 2 —O-alkyl and R 7 hydrogen or alkyl; or R 6 and R 7 form with the carbon atom which bears them a cyclic radical containing up to 8 carbon atoms. The compounds of formula (I) have antibiotic properties.
本发明涉及式(I)的化合物,其中Y为氧,N-Nalc 1或NOalc 2:X代表氢,羟基,烷基,烯基,炔基,烷氧基,CONOR或NRcRd,其中Rc和Rd为氢或烷基; Z代表氢,卤素或自由的,醚化或酯化的OH; R 2为氢或卤素; R 3为氢,烷基或卤素; R为氢或烷基; R 1为氢,烷基,烯基或炔基; R 5为氢或O-烷基; R 6为烷基或CH 2 —O-烷基,R 7为氢或烷基; 或R 6和R 7与它们所在的碳原子形成含有最多8个碳原子的环状基团。式(I)的化合物具有抗生素特性。